Kristina Masson, Ph.D., MBA, is Co-Founder and EVP, Business Operations at Acrivon Therapeutics, Inc. and President and CEO of the company´s research subsidiary Acrivon AB located in Medicon Village, Sweden. Here she has established all infrastructure, heads all operations, and runs the phospho- proteomic discovery hub and early drug programs for the company’s proprietary AP3 platform. In 2016, she founded and operated OncoSignature AB, a small biotech company focused on identifying predictive biomarkers for clinical-stage cancer therapeutics for U.S. companies. OncoSignature’s business was subsequently acquired by Acrivon AB. Prior to that, she was a Principal Scientist at Merrimack Pharmaceuticals, Cambridge, MA where she co-led, managed, and participated in cross-functional teams in both preclinical and clinical-stage therapeutic antibody programs, designing projects to identify predictive biomarkers, combination strategies and resistance mechanisms. Before joining Merrimack Pharmaceuticals, Kristina was a Post-Doctoral Fellow in the Golub lab at the Broad Institute of MIT and Harvard, developing assays for novel therapeutics and automated high-throughput drug screening approaches centered around synthetic lethality in cancer. Kristina received her M.Sc. and Ph.D. from Lund University, Sweden, and she received her Executive MBA from the Massachusetts Institute of Technology Sloan School of Management. Kristina is a member of the Board of Directors for Acrivon Therapeutics Inc. and Aqilion AB.